Use of an engineered ribozyme to produce a circular human exon.
We report the use of an engineered ribozyme to produce a circular human exon in vitro. Specifically, we have designed a derivative of a yeast self-splicing group II intron that is able to catalyze the formation of a circular exon encoding the first kringle domain (K1) of the human tissue plasminogen activator protein. We show that the circular K1 exon is formed with high fidelity in vitro. Furthermore, the system is designed such that the circular exon that is produced consists entirely of human exon sequence. Thus, our results demonstrate that all yeast exon sequences are dispensable for group II intron catalyzed inverse splicing. This is the first demonstration that an engineered ribozyme can be used to create a circular exon containing only human sequences, linked together at a precise desired ligation point. We expect these results to be generalizable, so that similar ribozymes can be designed to precisely create circular derivatives of any nucleotide sequence.
Mikheeva
S
S
Department of Pharmacology and Experimental Therapeutics, Boston University Medical Center, 80 East Concord Street, Boston, MA 02118, USA.
Hakim-Zargar
M
M
Carlson
D
D
Jarrell
K
K
D002384:Catalysis; D002414:Cations, Monovalent / Q000494:pharmacology; D004270:DNA, Circular / Q000096:biosynthesis* / Q000737:chemistry; D004271:DNA, Fungal / Q000235:genetics; D005091:Exons; D006801:Humans; D007438:Introns / Q000235:genetics; D018082:Kringles / Q000235:genetics; D015202:Protein Engineering; D012326:RNA Splicing / Q000187:drug effects; D016337:RNA, Catalytic / Q000378:metabolism*; D012441:Saccharomyces cerevisiae / Q000235:genetics; D013379:Substrate Specificity
D002414:Cations, Monovalent; D004270:DNA, Circular; D004271:DNA, Fungal; D016337:RNA, Catalytic